Compare iShares MSCI ACWI ETF (ACWI) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Alnylam Pharmaceuticals, Inc. — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ACWI | ALNY | |
|---|---|---|
52-Week High | $161.44 | $491.22 |
52-Week Low | $132.04 | $205.48 |
Market Cap | — | $29.60B |
Sector | — | Health |
Enterprise Value | — | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.65, up 0.34% today, with strong technical momentum showing bullish moving average signals. The ETF benefits from robust global earnings growth and investor inflows into equity ETFs, particularly in technology sectors. Recent institutional activity includes Bank of New York Mellon adjusting its position, while technical indicators show overbought conditions with RSI above 74.
The outlook remains positive given strong EPS growth and reasonable valuation at 15.5x forward P/E. Key risks include overbought technical conditions and market concentration in technology. Institutional sentiment appears constructive with continued ETF inflows supporting the global equity rally.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
